Ottawa Hospital Research Institute

NCT07662200

Early phase 1Not yet recruiting10 people23 Jun 2026clinicaltrials.gov

NCT05849129

CollaboratorPhase 2Recruiting90 people8 May 2023clinicaltrials.gov

NCT04871412

Phase 3Recruiting20 people4 May 2021clinicaltrials.gov

NCT04781725

Phase 2Status unknown90 people4 Mar 2021clinicaltrials.gov

NCT04780061

CollaboratorPhase 3Terminated90 people3 Mar 2021clinicaltrials.gov

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation

Phase 4Recruiting3,018 people24 Nov 2020clinicaltrials.gov

NCT04549207

Phase 4Active, not recruiting240 people16 Sept 2020clinicaltrials.gov

NCT04319627

Phase 3Recruiting2,700 people24 Mar 2020clinicaltrials.gov

NCT04243122

Phase 2Completed44 people28 Jan 2020clinicaltrials.gov

NCT03948568

Phase 4Completed262 people14 May 2019clinicaltrials.gov

NCT03664687

Phase 4Completed211 people10 Sept 2018clinicaltrials.gov

NCT03348696

Phase 4Completed124 people21 Nov 2017clinicaltrials.gov

NCT03211572

Phase 2Status unknown82 people7 Jul 2017clinicaltrials.gov

NCT03100123

Early phase 1Terminated1 person4 Apr 2017clinicaltrials.gov

NCT02998736

Phase 1Completed28 people20 Dec 2016clinicaltrials.gov

NCT02815319

Phase 4Completed60 people28 Jun 2016clinicaltrials.gov

NCT02721433

Phase 4Completed263 people29 Mar 2016clinicaltrials.gov

NCT02688803

Phase 4Terminated2 people23 Feb 2016clinicaltrials.gov

NCT02679664

Phase 2Status unknown312 people10 Feb 2016clinicaltrials.gov

NCT02306070

Phase 2Withdrawn0 people3 Dec 2014clinicaltrials.gov